Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Fluzoparib Consolidation in ES-SCLC
NCT04782089Phase 2Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and fluzoparib in small cell lung cancer (SCLC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival at 3 years. Status: unknown.
02
Drugs
camrelizumabfluzoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04782089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782089.